Cellomatics Biosciences, a Nottingham-based preclinical contract research organisation, is expanding its global client base by welcoming two new members of staff to support its business development efforts. Dr Pier Giorgio Amendola and Dr Jyoti Mundra have joined the company to assist with its expansion into both European and US markets.
Transitioning to the challenge of managing cultural differences and regional market dynamics, Pier will leverage his experience to navigate these challenges in European markets and establish strong local partnerships. He will focus on identifying new business opportunities, building and nurturing relationships with key stakeholders, and enhancing Cellomatics’ market footprint.
In Pier’s own words: “Cellomatics provides a dynamic, science-driven environment that enables close collaboration with clients and the delivery of tailored, innovative solutions. I value its high scientific standards and am eager to promote its capabilities to new clients, accelerating their drug development pipelines.”
Looking ahead to the US market, which is one of the biggest and most fast-growing biotech markets globally, Cellomatics aims to further expand its client base following recent export achievements. Jyoti’s appointment comes at an opportune time as the US seeks to collaborate with new markets following the BIOSECURE Act.
Jyoti, who is based in New Jersey, US, brings over 15 years of experience in business development roles at large US-based CROs. Her experience will be a valuable asset to Cellomatics as she helps accelerate the company’s growth and enhance its presence within the US.
In Jyoti’s words: “I am excited to bring my extensive business and scientific experience to help expand the customer base and provide US clients with the opportunity to benefit from Cellomatics’ pre-clinical expertise.”
Cellomatics’ CEO and founder Shailendra Singh expressed his excitement about the new appointments, stating: “Having worked with Pier for a number of years through Dompé, we are delighted that he has decided to join the Cellomatics team in a Business Development role.
His pharmaceutical sector experience has given him a deep understanding of our client needs, which will be crucial in building new relationships and achieving Cellomatics’ growth goals.
I am also thrilled to welcome Jyoti to the Cellomatics team. Her wealth of experience in executive leadership roles, deep understanding of the US market, and its work culture will be an invaluable asset to Cellomatics, and I look forward to working closely with her.”
